LiveWire Ergogenics (LVVV) AI Stock Analysis

• Market Cap: $1.21M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 168.87
• Revenue Growth: -81.39%
• EPS Growth: -100.00%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,511,245,200
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.15
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 2.15
• P/FCF Ratio: 5.15
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.01 ▲(1150.00% Upside)

The overall stock score for LiveWire Ergogenics is primarily driven by significant challenges in financial performance, including declining revenue and cash flow. The absence of technical indicators further impacts the score negatively. The lack of valuation data and earnings call information limits the ability to provide a more comprehensive assessment.

Positive Factors

Cost Management

Efficient cost management allows LiveWire Ergogenics to preserve margins despite declining revenue, indicating operational resilience.

Leverage Management

Improved leverage management suggests a more sustainable financial structure, enhancing long-term stability and reducing risk.

Cash Flow Stability

Maintaining a positive free cash flow to net income ratio indicates some level of cash flow stability, crucial for ongoing operations and investments.

Negative Factors

Revenue Decline

Significant revenue decline poses a risk to financial health, potentially impacting the company's ability to invest in growth and innovation.

Cash Generation Challenges

Decreased cash flow generation limits financial flexibility, affecting the company's capacity to fund operations and strategic initiatives.

Profitability Challenges

Declining net profit margins reflect challenges in maintaining profitability, which could hinder long-term growth and shareholder returns.

LiveWire Ergogenics Business Overview & Revenue Model

Company Description

LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based in Anaheim, California.

How the Company Makes Money

LiveWire Ergogenics generates revenue primarily through the sale of its CBD and hemp-derived products. The company has established a multi-channel distribution strategy that includes direct-to-consumer sales, partnerships with retail outlets, and e-commerce platforms. Key revenue streams include product sales, subscription services, and potential licensing agreements for its proprietary formulations. Additionally, the company's strategic partnerships with other entities in the cannabis industry enhance its market reach and provide opportunities for collaborative product development, further contributing to its earnings.

LiveWire Ergogenics Financial Statement Overview

Summary

Overall, LiveWire Ergogenics has shown a commendable transformation, with significant improvements in profitability and cash flow generation. High profit margins and improved operational efficiency are notable, although revenue growth volatility and moderate leverage remain concerns.

Income Statement

LiveWire Ergogenics has shown a strong improvement in its financial performance over the years. The company achieved a Gross Profit Margin of 97.59% in 2023, indicating efficient cost management. The Net Profit Margin also increased significantly to 56.40% in 2023, reflecting robust profitability. Revenue growth has been volatile, with a recent decline of 15.70% from 2022 to 2023, which might be a concern. However, the improved EBIT Margin of 50.79% and EBITDA Margin of 74.43% in 2023 underscore the company's enhanced operational efficiency.

Balance Sheet

The balance sheet of LiveWire Ergogenics reflects a mixed picture. The Debt-to-Equity Ratio is 1.07 in 2023, suggesting moderate leverage. The Return on Equity is notably high at 29.60%, indicating strong profitability relative to equity. The Equity Ratio, however, is 40.25%, indicating that a significant portion of assets is financed through equity. While the financial position has strengthened, the reliance on debt could pose risks if not managed properly.

Cash Flow

LiveWire Ergogenics has demonstrated improvement in cash flow generation. The Free Cash Flow grew significantly by 72.17% from 2022 to 2023, showcasing better cash management. The Operating Cash Flow to Net Income Ratio is 0.74, and the Free Cash Flow to Net Income Ratio is also 0.74, suggesting that earnings are effectively converting to cash. Despite these improvements, the company should continue focusing on maintaining cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.10M	304.12K	1.63M	1.94M	851.20K	580.32K
Gross Profit	1.07M	285.16K	1.59M	1.80M	701.55K	376.51K
EBITDA	884.44K	322.18K	1.22M	1.07M	-2.68M	-302.00K
Net Income	610.31K	78.72K	921.58K	684.12K	-3.43M	-1.60M
Balance Sheet
Total Assets	7.98M	7.96M	7.74M	6.27M	4.52M	2.91M
Cash, Cash Equivalents and Short-Term Investments	25.18K	11.27K	27.87K	76.38K	199.95K	109.88K
Total Debt	3.35M	3.35M	3.34M	3.20M	2.85M	3.23M
Total Liabilities	4.71M	4.70M	4.62M	4.24M	3.61M	3.99M
Stockholders Equity	3.26M	3.24M	3.11M	2.03M	912.13K	-1.08M
Cash Flow
Free Cash Flow	554.67K	124.74K	682.37K	396.37K	-467.21K	315.33K
Operating Cash Flow	554.68K	124.74K	682.37K	396.37K	-399.89K	356.16K
Investing Cash Flow	-608.74K	-187.34K	-857.40K	-1.20M	-930.51K	-874.12K
Financing Cash Flow	-46.89K	46.00K	126.51K	684.50K	1.42M	627.84K

LiveWire Ergogenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LVVV	41 Neutral	$1.21M	―	―	―	-81.39%	-100.00%
MSPR	38 Underperform	$1.58M	―	―	―	-8.57%	-52.17%
PRFX	34 Underperform	$3.38M	>-0.01	―	―	―	―
DRMA	15 Underperform	$2.43M	-0.09	-203.36%	―	―	90.53%